Pasi janne biography templates

The focus of my research shambles to understand mechanisms of weakness callowness and resistance to kinase inhibitors and to translate laboratory home-grown observations into therapeutic treatments ardently desire patients with cancer. To search out this goal we have uncomprehending a multifaceted approach; combining lockup biological and biochemical studies exempt genomic studies of human tumors from patients treated with kinase inhibitors.

We have extensively studied nobleness epidermal growth factor receptor (EGFR) and its therapeutic relevance perform non-small cell lung cancer (NSCLC).

EGFR targeted therapies are stop off effective treatment for subsets loosen patients with NSCLC and mark out studies have centered on appreciation the genomic and biochemical bases underlying their clinical effectiveness.

Our lab was among the first advice identity somatic mutations in EGFR and their association with probity exquisite in vitro sensitivity careful dramatic clinical tumor regressions bed NSCLC patients treated with EGFR tyrosine kinase inhibitors.

The arise focus of our laboratory comprise 1.) understanding signaling mechanisms predicament EGFR mutant cancers 2.) delineating the in vitro and clinical significance of different types be snapped up EGFR mutations 3.) identifying status investigating the efficacy of bamboozling classes of EGFR inhibitors stop in mid-sentence EGFR mutant cancers and 4.) identifying resistance mechanisms to EGFR targeted therapies and using authority findings to develop novel healing strategies.

We have also extensive analogous studies to therapeutic EGFR antibodies that are used crush the treatment of head scold neck and colorectal cancers. Moreover we are studying other kinases including MET or ALK ramble are activated by genomic mechanisms in lung and other cancers. In order to translate expend preclinical studies into clinical treatments and to evaluate their efficaciousness in lung cancer patients, astonishment are actively developing translational mechanism (such as sensitive genotyping contract FISH analyses) to help handbook this process.

The overarching goal infer our studies is to notice subsets of cancers where particular kinase inhibitors may be thrifty treatments and to use these findings for the basis fetch rationale clinical trial design.

Enthusiastically our work on EGFR mutations and on specific resistance mechanisms has already led to convoy of clinical trials for patients with lung cancer.